Office Location: 836 Southwest Tower
660 S. Euclid Ave.
Campus Box 8127
St. Louis, MO 63110
Office Phone: (314) 747-3979
Fax: (314) 362-7641
Email Address: firstname.lastname@example.org
Rachel is a native of Arkansas. She attended the University of Arkansas for her B.S. in Microbiology where she continues to proudly support Arkansas Razorback football. She graduated from the University of Texas Southwestern Medical School in 2009 and then traveled to St Louis and Washington University for her training in internal medicine which she completed in 2012. During residency, Rachel worked on a research project headed by Dr. Garry Tobin aimed at lowering the rate of episodes of inpatient hypoglycemia at Barnes-Jewish hospital. She presented part of her work at the American Diabetes Association meeting in June of 2012. Rachel is happily married to her husband, Denton, of 7 years and stays busy at home chasing around and caring for her young daughter, Madelyn.
Obesity and diabetes continues to remain an ever-growing problem in the United States and around the world and will continue to worsen as lifestyles continue to remain sedentary. Investigation into pharmacological therapies for people with type 2 diabetes remains at the forefront of drug development in the pharmaceutical industry. One drug that has been available for the treatment of malaria and rheumatologic conditions such as rheumatoid arthritis and systemic lupus erythematosis for many years, Hydroxychloroquine, as been observed to reduce the incidence of type 2 diabetes in patients treated with this drug. Additionally, it has been shown to have beneficial effects on glycemia in patients with type 2 diabetes. Hydroxychloroquine specifically has been shown to reduce fasting plasma glucose levels, improve insulin sensitivity, to reduce insulin clearance, to lower LDL, and it has a favorable safety profile which allows it to be used safely in patients who take it long-term.
Rachel, along with her mentors, are conducting a randomized, double-blind, placebo-controlled trial in patients with diabetes which will examine the effect of hydroxychloroquine on insulin resistance and hepatic glucose output. Patients receive either placebo or hydroxychloroquine at a dose of 400mg daily in addition to their other usual oral hypoglycemic agents for one month. Insulin sensitivity and hepatic glucose output as well as other metabolic parameters are evaluated before and after taking the study drug with the use of insulin clamp procedures. The aim of this study is to delineate if hydroxychloroquine should be evaluated further for use in diabetic patients as a potential mainstream therapy.